Literature DB >> 10998482

The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels.

A A Kroon1, M A van't Hof, P N Demacker, A F Stalenhoef.   

Abstract

We studied the rebound of lipoproteins in 20 hypercholesterolemic men [mean total cholesterol (TC) levels 9.6+/-1.8 mmol/l] after LDL-apheresis (LA) to determine the rate of recovery and the change in cholesterol synthesis, and to find a uniform estimation for time-averaged levels. After 10-20 months on biweekly LA using dextran sulfate cellulose columns and concomitant simvastatin administration, time-averaged levels (+/-SD) measured by integration of the area under the curve were as follows: TC 4.4+/-1.0 mmol/l, LDL cholesterol (LDL-C) 2.5+/-1.0 mmol/l, apolipoprotein B (apo B) 1. 3+/-0.3 g/l, triglycerides (TG) 1.7+/-0.7 mmol/l, HDL-C 1.1+/-0.2 mmol/l, and lipoprotein(a) [Lp(a)] 53.7+/-49.4 mg/dl. Mean acute reductions in TC, LDL-C, apo B, Lp(a), and TG were 61, 77, 75, 76, and 62%, respectively. HDL-C levels were not influenced. Median recovery half times for TC, LDL-C, apo B, and Lp(a) were 3.0, 4.0, 2. 3, and 3.5 days, respectively. The rebound of Lp(a) was identical to LDL-C, in 12 and 13 days post-treatment, respectively, whereas apo B and TC returned to pre-treatment levels in 7.5 and 10 days, respectively, due to the fast rebound of VLDL particles. Notwithstanding these differences, time-averaged levels (C(AVG)) could be estimated uniformly for the four latter parameters with the formula: C(AVG)=C(MIN)+0.73(C(MAX)-C(MIN)), where C(MAX) and C(MIN) are the immediate pre- and post-treatment levels. During long-term treatment the whole-body cholesterol synthesis was increased as measured by the ratio lathosterol to cholesterol of 3.24+/-1.49 mmol/mmol, whereas no further transient increase in the recovery period after LA was found. In conclusion, long-term LA and simvastatin therapy induced acute and chronic changes in lipids and lipoproteins showing the feasibility of biweekly treatment. It was shown that time-averaged levels, as a measure for the effective plasma levels, can be accurately estimated from pre- and post-treatment levels only.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10998482     DOI: 10.1016/s0021-9150(00)00371-3

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  31 in total

1.  LDL-apheresis therapy.

Authors:  Patrick M Moriarty
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-08

2.  Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis.

Authors:  Hagai Tavori; Ilaria Giunzioni; MacRae F Linton; Sergio Fazio
Journal:  Circ Res       Date:  2013-10-11       Impact factor: 17.367

Review 3.  Lipoprotein apheresis.

Authors:  Vijay G Bhoj; Bruce S Sachais
Journal:  Curr Atheroscler Rep       Date:  2015-07       Impact factor: 5.113

4.  Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment.

Authors:  Kurt Derfler; Sabine Steiner; Helmut Sinzinger
Journal:  Wien Klin Wochenschr       Date:  2015-07-23       Impact factor: 1.704

5.  Long-term lipoprotein apheresis in the treatment of severe familial hypercholesterolemia refractory to high intensity statin therapy: Three year experience at a lipoprotein apheresis centre.

Authors:  Agnieszka Mickiewicz; Justyna Borowiec-Wolna; Witold Bachorski; Natasza Gilis-Malinowska; Rafał Gałąska; Grzegorz Raczak; Magdalena Chmara; Bartosz Wasąg; Miłosz J Jaguszewski; Marcin Fijałkowski; Marcin Gruchała
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

6.  The Italian Consensus Conferences on low density lipoprotein-cholesterol apheresis.

Authors:  Anja Vogt
Journal:  Blood Transfus       Date:  2016-07-07       Impact factor: 3.443

7.  The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

Authors:  C Stefanutti; D J Blom; M R Averna; E A Meagher; H dT Theron; A D Marais; R A Hegele; C R Sirtori; P K Shah; D Gaudet; G B Vigna; B S Sachais; S Di Giacomo; A M E du Plessis; L T Bloedon; J Balser; D J Rader; M Cuchel
Journal:  Atherosclerosis       Date:  2015-03-14       Impact factor: 5.162

8.  Multimodal lipid-lowering treatment in pediatric patients with homozygous familial hypercholesterolemia-target attainment requires further increase of intensity.

Authors:  Günter Klaus; Christina Taylan; Rainer Büscher; Claus Peter Schmitt; Lars Pape; Jun Oh; Joenna Driemeyer; Matthias Galiano; Jens König; Carsten Schürfeld; Ralf Spitthöver; Juergen R Schaefer; Lutz T Weber; Andreas Heibges; Reinhard Klingel
Journal:  Pediatr Nephrol       Date:  2018-03-03       Impact factor: 3.714

9.  Plasmapheresis for hypertriglyceridemia: The association between blood viscosity and triglyceride clearance rate.

Authors:  Hung-Chieh Wu; Lin-Chien Lee; Wei-Jie Wang
Journal:  J Clin Lab Anal       Date:  2018-10-15       Impact factor: 2.352

10.  Low-density lipoprotein apheresis: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2006-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.